3D Medicines Inc. (HKG:1244)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.750
+0.140 (3.88%)
Apr 17, 2026, 4:08 PM HKT
Market Cap920.19M -0.9%
Revenue (ttm)396.26M -20.1%
Net Income-197.56M
EPS-0.80
Shares Out245.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume68,500
Average Volume92,334
Open3.710
Previous Close3.610
Day's Range3.700 - 3.830
52-Week Range2.830 - 10.020
Beta0.27
RSI42.93
Earnings DateMar 31, 2026

About 3D Medicines

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and other drug candidates for the treatment of patients with various cancers in the People’s Republic of China. The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC; and in P... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 183
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1244
Full Company Profile

Financial Performance

In 2025, 3D Medicines's revenue was 356.09 million, a decrease of -20.10% compared to the previous year's 445.65 million. Losses were -177.53 million, -2.81% less than in 2024.

Financial numbers in CNY Financial Statements